JAMP Pharma Recalls Pain Medication Over Dangerous Mix-Up
Quebec’s JAMP Pharma Corp. has issued an urgent recall of one lot of its JAMP-Pregabalin pain medication after discovering a potentially life-threatening labeling error. Bottles labeled as containing 50-milligram capsules may actually hold much stronger 150-milligram capsules, Health Canada revealed in a rare Saturday night alert.
Overdose Fears Prompt Swift Action
The recall targets lot number 2305012747, with an expiry date of August 2026. Health Canada warns that patients unknowingly taking a higher dose could suffer an overdose, which may result in serious or even fatal health risks. JAMP-Pregabalin is prescribed for nerve pain, fibromyalgia, and related conditions.
What Patients and Pharmacists Should Do
Health Canada urges patients and pharmacists to inspect all JAMP-Pregabalin 50mg bottles immediately. If any 150mg capsules are found, or if there’s uncertainty, the medication should be returned to the pharmacy right away. Symptoms of overdose include mood changes, confusion, drowsiness, agitation, and seizures. Anyone experiencing these signs should seek emergency medical help.
Company and Government Respond
JAMP Pharma says no patients have been harmed so far and stresses the recall was initiated proactively in partnership with Health Canada. The agency is monitoring the company’s investigation and corrective measures to prevent future incidents.
Safety Reminders for Patients
Patients are also cautioned not to stop taking pregabalin abruptly, as withdrawal can cause additional health issues. If you have questions or concerns about your medication, consult your pharmacist or healthcare provider for guidance.
Stay alert: always double-check your prescriptions and report any irregularities to your pharmacy for your safety.
